{"id":"NCT00296504","sponsor":"ViiV Healthcare","briefTitle":"A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects","officialTitle":"An Open-Label Phase III Study to Assess the Long Term Safety Profile of GW433908 Containing Regimens in HIV-1 Infected Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2001-11","primaryCompletion":"2010-10","completion":"2010-10","firstPosted":"2006-02-27","resultsPosted":"2011-11-08","lastUpdate":"2013-04-19"},"enrollment":753,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Infection, Human Immunodeficiency Virus"],"interventions":[{"type":"DRUG","name":"fosamprenavir (GW433908)","otherNames":[]},{"type":"DRUG","name":"ritonavir","otherNames":["fosamprenavir (GW433908)"]}],"arms":[],"summary":"GW433908 (fosamprenavir; FPV)is a pro-drug of amprenavir (APV) which is more water soluble and can be formulated into a tablet with a reduced pill burden (four 700mg tablets of FPV versus sixteen 150mg capsules daily for APV. This study is designed to provide additional information on long term safety and tolerability of FPV containing regimens for those subjects who received FPV in previous GlaxoSmithKline studies.","primaryOutcome":{"measure":"Number of Participants With Any Adverse Event (AE): Interim Analysis","timeFrame":"Baseline (Day 1) up to 31 January 2006 (up to Week 264)","effectByArm":[{"arm":"FPV Population (APV30001)","deltaMin":117,"sd":null},{"arm":"NFV Population (APV30001)","deltaMin":16,"sd":null},{"arm":"FPV Population (APV30002)","deltaMin":215,"sd":null},{"arm":"NFV Population (APV30002)","deltaMin":52,"sd":null},{"arm":"FPV/RTV QD Population (APV30003)","deltaMin":72,"sd":null},{"arm":"FPV/RTV BID Population (APV30003)","deltaMin":75,"sd":null},{"arm":"PI-Na√Øve Population (Other Studies)","deltaMin":95,"sd":null},{"arm":"PI-Experienced Population (Other Studies)","deltaMin":68,"sd":null}],"pValues":[]},"eligibility":{"minAge":"13 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":24,"countries":["United States","Brazil","Chile","France","Italy","Portugal","Spain","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":33,"n":119},"commonTop":["Diarrhoea","Upper respiratory tract infection","Nausea","Nasopharyngitis","Headache"]}}